On March 16, 2026, BioMarin Pharmaceutical Inc. announced it will stop dosing and enrollment in Phase 2 trials for VOXZOGO in Turner Syndrome, SHOX-deficiency, and ACAN-deficiency due to slipped capital femoral epiphysis events, though trials continue for Noonan syndrome and idiopathic short stature patients.